Amarin to Participate in the H.C. Wainwright 21st Annual Global Investment Conference
Last amarin corp plc ads earnings: 4/30 05:00 am
Check Earnings Report
US:NASDAQ Investor Relations: investor.amarincorp.com/investors
BEDMINSTER, N.J. and DUBLIN, Ireland, Aug. 28, 2019 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that John F. Thero, Amarin's president and chief executive officer, is scheduled to present a general company update at the H.C. Wainwright 21st Annual Global Investment Conference on Monday, September 9, 2019, from 8:45-9:10 a.m. Eastern Time in New York City. A live audio webcast of the presentation will be available at: http://www.amarincorp.com, and will be accessible at the same link for 30 days. About Amarin Amarin Corporation plc. is a rapidly growing, innovative pharmaceutical company focused on developing therapeutics to improve cardiovascular health. Amarin’s product development program leverages its extensive experience in polyunsaturated fatty acids and lipid science. Vascepa (icosapent ethyl) is Amarin's first FDA-approved
[Read more]
| Impact snapshot | Event time: | AMRN | ||||
|---|---|---|---|---|---|---|
|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last price | ||
| VWAP | ||
|
High:
|
Max up |
High:
|
|
Low:
|
Max down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event Day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance Since Event
Time and Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
SIGN UP TODAY
Opt-in for
AMRN alerts
AMRN alerts
from News Quantified
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AMRN alerts
High impacting Amarin Corp Plc ADS news events
Weekly update
A roundup of the hottest topics
AMRN
News
- Amarin to Report Second Quarter and Six Month 2021 Financial Results and Host Conference Call on August 5, 2021GlobeNewswire
- Pharmaceutical Executive® APEX Awards Announces 2021 FinalistsPR Newswire
- Amarin Co. plc (<a href="https://www.marketbeat.com/stocks/NASDAQ/AMRN/price-target/">NASDAQ: AMRN</a>) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "strong-buy" rating. They now have a $5.50 price targMarketBeat
- U.S. Supreme Court denies Amarin's bid to revive Vascepa drug patents [Financial Post (Toronto, Ontario, Canada)]Financial Post
- U.S. Supreme Court denies Amarin's bid to revive Vascepa drug patents [Financial Post (Toronto, Ontario, Canada)]Financial Post
- More
AMRN
SEC Filings
- 7/2/21 - Form 4
- 7/2/21 - Form 4
- 7/2/21 - Form 4
- AMRN's page on the SEC website
- More